Annual report pursuant to Section 13 and 15(d)

LICENSED TECHNOLOGY (Details)

v3.7.0.1
LICENSED TECHNOLOGY (Details)
12 Months Ended
Dec. 31, 2016
USD ($)
LicensingAgreement
Dec. 31, 2015
USD ($)
shares
Research and Development Arrangement, Contract to Perform for Others [Line Items]    
License fee payable $ 0 $ 4,000,000
Licensed Technology [Abstract]    
Licensed technology 9,608,000 7,156,000
Less accumulated amortization 1,224,000 547,000
Licensed technology, net 8,384,000 6,609,000
Amortization on licensed technology 677,000 538,000
Amortization expense for intangible assets [Abstract]    
2017 812,000  
2018 812,000  
2019 812,000  
2020 812,000  
2021 812,000  
Thereafter 4,324,000  
Licensed technology, net $ 8,384,000 6,609,000
Abeona Therapeutics LLC [Member]    
Research and Development Arrangement, Contract to Perform for Others [Line Items]    
Period of amortization of license 20 years  
Plasma Technologies LLC [Member]    
Research and Development Arrangement, Contract to Perform for Others [Line Items]    
Period of amortization of license 11 years  
License fee paid   1,000,000
License fee payable   $ 4,000,000
License fee payable in common stock (in shares) | shares   1,096,151
Milestone payment in common stock (in shares) | shares   513,375
EB Agreement [Member]    
Research and Development Arrangement, Contract to Perform for Others [Line Items]    
Number of license agreements | LicensingAgreement 2  
Gene Therapy EB-201 [Member]    
Research and Development Arrangement, Contract to Perform for Others [Line Items]    
Period of amortization of license 20 years